Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 90, Issue 2, Pages 304-312Publisher
WILEY
DOI: 10.1002/jmv.24903
Keywords
daclatasvir; direct acting antivirals; HCV; HIV; ledipasvir
Categories
Funding
- German Research Agency
- German Center for Infection Research
Ask authors/readers for more resources
There are limited data regarding the real world effectiveness of direct acting antivirals (DAA) for the therapy of chronic genotype 3 hepatitis C virus (HCV) infection. All HCV genotype 3 infected patients from the German hepatitis C cohort (GECCO), which is a prospective database of nine German hepatitis C treatment centers, were included in the study. Three hundred forty-two chronically infected HCV genotype 3 patients were analyzed (253 males [74.0%], mean age 47.3 years, 127 cirrhotic patients [37.1%] mostly with Child A cirrhosis, 113 treatment experienced patients [37.1%], 38 HCV/HIV co-infected patients [11.1%]). SVR12 rates in the intention-to-treat analysis were as follows: sofosbuvir/ribavirin 69.4% (75/108), sofosbuvir/peginterferon/ribavirin 80.6% (58/72), sofosbuvir/daclatasvir +/- ribavirin for 12 weeks 88.3% (53/63), sofosbuvir/daclatasvir +/- ribavirin for 24 weeks 79.3% (23/29), sofosbuvir/ledipasvir +/- ribavirin for 12 weeks 71.4% (10/14), and sofosbuvir/ledipasvir +/- ribavirin for 24 weeks 86.7% (26/30). Forty patients were lost to follow-up, 23 patients had a relapse, 4 patients stopped treatment prematurely and 1 patient died. Female sex (P=0.038) and treatment with two different DAAs (P=0.05) were predictors for SVR12 in the multivariate analysis. In conclusion, sofosbuvir/daclatasvir +/- ribavirin for 12 weeks and sofosbuvir/ledipasvir +/- ribavirin for 24 weeks are effective for the treatment of HCV genotype 3 infected patients including cirrhotic, treatment-experienced or HIV/HCV co-infected patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available